Søgning på udtrykket 'covid-19' giver 84 resultater
Dokumenter [11] Sider [3] Kalender [29] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [11]
Dette notat omfatter patienter med følger efter infektion med SARS-CoV-2. Aktuelt defineres vedvarende symptomer ≥4 uger efter infektionsstart som langvarige symptomer, og vedvarende symptomer ≥12 uger anses som senfølger efter COVID-19.
Invitation til møde den 20. maj 2022
Ændringer siden sidste udgave: 1. Simplificering af risikogrupper. 2. Skærpelse af kriterier for opstart af behandling hos indlagte patienter, f.eks. blodgas analyse før remdesivir. 3. Information om høj pris på paxlovid og højere NNT for beskyttelse mod alvorligt forløb siden primærpublikation.
COVID-19 pandemien: Erfaringer vedrørende migranter og etniske minoriteters sundhed
Virtuelt årsmøde med fokus på COVID-19 den 7. maj 2021
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: Remdesivir står ikke længere som relativt kontraindiceret ved påvirket nyrefunktion.
Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: 1. Et af Paxlovid kriterierne ændret (fra ”Betydelige symptomer på COVID-19” til ”Mild eller moderat COVID-19”). 2. Døde links til infektionshygiejniske retningslinjer er fjernet, og nyt er indsat. 3. Tekst om afisolation.
DSI anbefaler fortsat remdesivir ved indlæggelsekrævende COVID-19 med behov for tilskud af ilt, hvor iltmætningen i blodet er under 94% uden ilttilskud hos ellers lungeraske og, at hvor der ved røntgen af thorax påvises infiltrat(er). Dette holdningspapir omhandler baggrunden for anbefalingen.
Indlæg af formand Rikke Krogh-Madsen i Altinget om opgradering af det infektionsmedicinske speciale
Vurdering af behov for antivirale midler og effekt af SARS-CoV2 infektion i de risikogrupper, som ifølge gældende retningslinjer skal tilbydes behandling med lægemidlet.
Afholdt fredag den 25. september 2020 som onlinemøde med fokus på COVID-19
Sider [3]
… Borrelia: Anne-Mette Lebech (tovholder), Christian Brandt, Fredrikke Christie Knudtzen, Helene Mens, Jacob Bodilsen, Sigurdur Skarphédinsson Borrelia klaringsrapport (2014), Diagnostik og behandling af Lyme neuroborreliose (2021), COVID-19: Behandling af COVID-19: Michael Dalager-Pedersen (tovholder), Marie Helleberg, Gitte Kronborg, Isik Somuncu, Merete Storgaard, Lothar Wiese COVID-19 retningslinje (2024v28), Post-COVID-19: Jacob Bodilsen, Christian Brandt, Stine Jo…
…diagnostiske undersøgelser ikke forsinke empirisk behandling ved symptomer herpå. Vaccinationer: Primær vaccination foretages mod Streptococcus pneumoniae, Haemophilus influenzae type B og Neisseria meningitidis. Årlig influenza-vaccination (samt COVID-19 vaccination ud fra aktuelle rekommandationer) anbefales på grund af øget risiko for sekundær bakteriel infektion. Pneumokokker. Den 20-valent konjugerede pneumokok vaccine, PCV20 (Apexxnar), anbefales til voksne. Apexxnar er en…
Professor Henrik Nielsen kommenterer: Så kom den endelig. Længe ventet, med spænding imødeset. Fagfællebedømt artikel om BioNTech/Pfizers BNT162b2 mRNA vaccine mod COVID-19. Selvfølgelig i NEJM og naturligvis af stor aktuel interesse, men vil også blive stående som en klassiker i medicinsk litteratur. En milepæl i vaccinologiens historie, blandt andet fordi der er anvendt en ny teknologisk platform og fordi studiet er kommet i mål på rekordtid. Alle infektionsmedicinere bør kende denne publikat…
Kalender [29]
16. januar 2023, Online
14. december 2022, Online
11. oktober 2022, Online
20. maj 2022, Aarhus Universitet
21. marts 2022, Aarhus Universitetshospital, Skejby
9. februar 2022, Online
4. januar 2022, Online
7. december 2021, Online
4. november 2021, Online
23. september 2021, Aarhus
21. september 2021, Online
31. august 2021, Holst Auditoriet, Mærsk Tårnet, København
16. juni 2021, Online
27. maj 2021, Online
7. maj 2021, Online
13. april 2021, Online
23. marts 2021, Online
22. marts 2021, Online
16. marts 2021, Online
3. februar 2021, Online
28. januar 2021, Online
19. januar 2021, Online
30. december 2020, Online
9. oktober 2020, Århus og online
25. september 2020, Online
28. juni 2020, Online
18. juni 2020, Aflyst på grund af COVID-19
3. juni 2020, Mødet udskudt på grund af COVID-19
24. marts 2020, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Clinical Microbiology and Infection
27.07.2024
Plasma collected from recovered COVID-19 patients (COVID-19 convalescent plasma, CCP) was the first antibody-based therapy employed to fight the COVID-19 pandemic. While the therapeutic effect of early administration of CCP in COVID-19 outpatients has been recognized, conflicting data exist regarding the efficacy of CCP administration in hospitalized patients.
Lancet
26.07.2024
Several employees of the Prevent Senior hospital chain have been charged over the care of patients during the COVID-19 pandemic. Marcia Triunfol reports.
International Journal of Infectious Diseases
26.07.2024
The World Health Organization's (WHO) Pandemic and Resilience for Emerging Threats (PRET) initiative calls for the formulation of preparedness plans and priority actions underpinned by learnings from the COVID-19 pandemic [1]. Yet, four years on from the emergence of SARS-CoV-2, the true burden of the pandemic and the impact of constraints to scale-up mitigation strategies in resource-limited settings remain poorly understood. Systematic issues with epidemiological surveillance data have been highlighted as…
BMJ Open
26.07.2024
. Objective. To assess the level of compliance with COVID-19 preventive measures and compliance-associated factors in the Rwanda community. . Design. Cross-sectional study. . Settings. Country-wide community survey in Rwanda. . Participants. 4763 participants were randomly sampled following the sampling frame used for the recent Rwanda Demographic Health Survey. Participants were aged between 22 years and 94 years. . Outcomes. The participants’ compliance with three preventive measures (wearing a face…
BMJ Open
26.07.2024
. Objective. This study aimed to identify the primary sources of COVID-19 health information for adolescent girls in Sierra Leone and evaluate their perceived trustworthiness and influence on their behaviour. . Design. Using a convenience sampling strategy grounded in the social cognitive theory, the study explored adolescents' navigation and appraisal of health information sources, their understanding of COVID-19, and the impact of societal and observational influences on their health beliefs and actions.…
BMJ Open
26.07.2024
. Objective. Reductions in paediatric unscheduled healthcare utilisation were seen during the COVID-19 pandemic, with concerns around their impact on children’s health. The reasons for these changes are not well described. This review aims to explore the factors reported by parents that influenced their decision-making around accessing paediatric unscheduled healthcare during the COVID-19 pandemic. . Design. Mixed methods rapid review and thematic synthesis based on the Enhancing Transparency of Reportin…
BMJ Open
26.07.2024
…opurinol on the cardiovascular system. The randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome (ALL-VASCOR) study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk excluding ischaemic heart disease. This is particularly important due to t…
BMC Infectious Diseases
25.07.2024
. Abstract. . Background. The global impact of the coronavirus disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality. Immunocompromised patients, particularly those treated for B-cell lymphoma, have shown an increased risk of persistent infection with SARS-CoV-2 and severe outcomes and mortality. Multi-mutational SARS-CoV-2 variants can arise during the course of such persistent cases of COVID-…
BMC Infectious Diseases
25.07.2024
. Abstract. . Background. Evidence on ivermectin as a treatment for Covid-19 is controversial. A Cochrane review concluded that the efficacy and safety of ivermectin is uncertain (evidence up to April 2022) and WHO recommended its use only in the setting of clinical trials. This study aimed to assess the efficacy and safety of oral ivermectin in hospitalized patients with mild to moderate Covid-19. . . …
Science
25.07.2024
Science, Volume 385, Issue 6707, Page 396-401, July 2024.
Clinical Infectious Diseases
25.07.2024
New England Journal of Medicine
25.07.2024
New England Journal of Medicine, Ahead of Print.
Critical Care Explorations
25.07.2024
BACKGROUND AND OBJECTIVE: . To develop the COVid Veteran (COVet) score for clinical deterioration in Veterans hospitalized with COVID-19 and further validate this model in both Veteran and non-Veteran samples. No such score has been derived and validated while incorporating a Veteran sample. DERIVATION COHORT: . Adults (age ≥ 18 yr) hospitalized outside the ICU with a diagnosis of COVID-19 for model development to the Veterans Health Administration (VHA) (n = 80 hospitals). VALIDATION COHORT: . Externa…
Critical Care Explorations
25.07.2024
… the various pandemic phases; we also emphasize the need for an ongoing clinical network to improve the understanding of known and novel respiratory viral diseases. OBJECTIVES: . To describe how patient characteristics and care evolved across the various COVID-19 pandemic periods in those hospitalized with viral severe acute respiratory infection (SARI). DESIGN: . Severe Acute Respiratory Infection-Preparedness (SARI-PREP) is a Centers for Disease Control and Prevention Foundation-funded, Society of Criti…
Critical Care Explorations
25.07.2024
OBJECTIVE: . During the COVID-19 pandemic, some centers converted intermediate care units (IMCUs) to COVID-19 ICUs (IMCU/ICUs). In this study, we compared adherence to lung protective ventilation (LPV) and outcomes for patients with COVID-19-related acute respiratory distress syndrome (ARDS) treated in an IMCU/ICU versus preexisting medical ICUs (MICUs). DESIGN: . Retrospective observational study using electronic medical record data. SETTING: . Two academic medical centers from March 2020 to September 2…
Critical Care Explorations
25.07.2024
OBJECTIVES (BACKGROUND): . Under normal conditions, pulmonary megakaryocytes are an important source of circulating thrombocytes, causing thrombocyte counts to be higher in arterial than venous blood. In critical COVID-19, thrombocytes may be removed from the circulation by the lungs because of immunothrombosis, possibly causing venous thrombocyte counts to be higher than arterial thrombocyte counts. In the present study, we investigated time-dependent changes in pulmonary turnover of thrombocytes during c…
PLoS One Infectious Diseases
24.07.2024
by Kyung-Shin Lee, Min Jin Go, Youn Young Choi, Min-Kyung Kim, Jaehyun Seong, Ho Kyung Sung, Jaehyun Jeon, Hee-Chang Jang, Myoung-Hee Kim .
PLoS One Infectious Diseases
24.07.2024
by Daniela Tregnago, Alice Avancini, Lorenzo Belluomini, Ilaria Trestini, Marco Sposito, Jessica Insolda, Federica Bianchi, Teodoro Sava, Chiara Gaiani, Lidia Del Piccolo, Valentina Guarneri, Giuseppe Verlato, Ahmad Tfaily, Roberta Vesentini, Serena Zuliani, Sara Pilotto, Michele Milella .
PLoS One Infectious Diseases
24.07.2024
by Namoonga M. Mantina, Maiya G. Block Ngaybe, Katharine H. Zeiders, Kayla M. Osman, Ada M. Wilkinson-Lee, Antoinette M. Landor, Lindsay T. Hoyt . Introduction The Latinx population has the second highest COVID-19 death rate among racial/ethnic groups in the United States and less than half of Latinx youth aged 5–17 years old completed their COVID-19 primary vaccination series as of September 2022. COVID-19 vaccine misinformation detrimentally impacts vaccination rates. In this study, we examined factors…
BMC Infectious Diseases
24.07.2024
. Abstract. . Background. Evidence on ivermectin as a treatment for Covid-19 is controversial. A Cochrane review concluded that the efficacy and safety of ivermectin is uncertain (evidence up to April 2022) and WHO recommended its use only in the setting of clinical trials. This study aimed to assess the efficacy and safety of oral ivermectin in hospitalized patients with mild to moderate Covid-19. . . …
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?Eurosurveillance latest updates
20.07.2024
. Background. The COVID-19 pandemic and the emergence of Candida auris have changed the epidemiological landscape of candidaemia worldwide. . . Aim. We compared the epidemiological trends of candidaemia in a Greek tertiary academic hospital before (2009–2018) and during the early COVID-19 (2020–2021) and late COVID-19/early post-pandemic (2022–2023) era. . . Methods. Incidence rates, species distribution, antifungal susceptibility profile and antifungal consumption were recorded, and one-way ANO…
Eurosurveillance latest updates
12.07.2024
. Background. As Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating. . . Aim. This study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in i…
Eurosurveillance latest updates
22.06.2024
. Background. Non-severe adverse events (AE) including pain at injection site or fever are common after COVID-19 vaccination. . . Aim. To describe determinants of AE after COVID-19 vaccination and investigate the association between AE and pre- and post-vaccination antibody concentrations. . . Methods. Participants of an ongoing prospective cohort study (VASCO) completed a questionnaire on AE within 2 months after vaccination and provided 6 monthly serum samples during May 2021–November 2022. Logist…
Eurosurveillance latest updates
17.05.2024
.
Medscape Infectious Diseases
16.05.2024
CDC experts share what clinicians should know about COVID-19 prevention in immunocompromised patients. . CDC Expert Commentary
Morbidity and Mortality Weekly Report (MMWR)
26.04.2024
This report describes a recommendation from the Advisory Committee on Immunization Practices that all people ages ≥65 years and older receive one additional dose of any updated (2023-2024 Formula) COVID-19 vaccine.
Morbidity and Mortality Weekly Report (MMWR)
19.04.2024
This report describes COVID-19 rates, hospitalizations, and vaccination coverage among nursing home residents.
Morbidity and Mortality Weekly Report (MMWR)
19.04.2024
This report describes the duration of protection provided by the original monovalent COVID-19 vaccines.
ECDC COVID-19 updates
17.04.2024
This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
Eurosurveillance latest updates
12.04.2024
…ropean Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season. .
Morbidity and Mortality Weekly Report (MMWR)
12.04.2024
This report describes a review of Oregon death certificate data to assess whether young people in Oregon might be dying after receiving a COVID-19 vaccine.
Morbidity and Mortality Weekly Report (MMWR)
12.04.2024
This report describes COVID-19 vaccination coverage in the World Health Organization African Region during 2021-2023.
ECDC COVID-19 updates
8.04.2024
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Morbidity and Mortality Weekly Report (MMWR)
5.04.2024
This report describes the number of COVID-19 bivalent vaccine doses administered by Federal Retail Pharmacy Program partners.
Medscape Infectious Diseases
5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. . Medscape Medical News
Medscape Infectious Diseases
1.04.2024
The findings of this study, which focused on the early phases of the COVID-19 pandemic, may be useful to administrators and policymakers in case of a future pandemic outbreak. . Medscape Medical News
Eurosurveillance latest updates
29.03.2024
…iod. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. . . Results. Among adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Eurosurveillance latest updates
29.03.2024
. Background. Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. . . Aim. To describe, for children aged
Morbidity and Mortality Weekly Report (MMWR)
29.03.2024
This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.
Medscape Infectious Diseases
28.03.2024
There is no increased risk for stroke during the 6 weeks following receipt of either brand of the COVID-19 bivalent vaccine, new research shows. . Medscape Medical News